Rise Nano Optics Announces Strategic Partnership with Sierra Optical Lab to Produce and Commercialize SpectraGuard(TM) Lenses in the United States
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced a strategic partnership with Sierra Optical Lab ("Sierra Optical"), an independent wholesale optical laboratory and VSP®-Authorized Lab, located in Reno, Nevada, to support the production and commercialization of its SPECTRAGUARD™ lens technology in the...
2026-04-20 7:00 AM EDT
Rise Nano Optics Announces FDA Class I Device Classification for SPECTRAGUARD(TM) Nano-Optic Lens Technology
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that its proprietary, patented SPECTRAGUARD™ nano-optic lens technology is FDA registered and has been classified by the U.S. Food and Drug Administration (FDA) as a Class I exempt medical device. The FDA has accepted the Company's stated intended use claim...
2026-03-23 7:00 AM EDT
Rise Nano Optics Appoints Erik Ritchie as Chief Commercial Officer to Lead North American Commercialization Strategy
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced the appointment of Erik Ritchie as Chief Commercial Officer (CCO). Mr. Ritchie will lead Rise's North American commercialization strategy, overseeing go-to-market execution, operations, partnerships, and sales and marketing. Mr. Ritchie brings deep executive...
2026-03-17 7:00 AM EDT
Rise Nano Optics to Commence Trading on the Canadian Securities Exchange Under the Symbol "EYE", Today, March 12, 2026
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"). Trading is expected to commence on the CSE under the symbol "EYE" at the open of markets on March 12, 2026. Inas Said, CEO of Rise commented, "Listing publicly represents an important milestone for Rise Nano Optics and...
2026-03-12 7:00 AM EDT
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health technology innovator specializing in nano-optic solutions that effectively block wavelengths of light linked to vision stress and degenerative eye disease, is pleased to announce the granting of its third U.S. technology patent – U.S. Patent No. 12,383,955 (B2) – further strengthening its proprietary leadership position in advanced eye-protection nanomaterials....
2025-11-04 7:00 AM EST
Rise Health Nano Optics Achieves FDA Clearance Milestone Following Successful Biocompatibility Testing for EYEGUARD Lenses
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health-tech innovator specializing in advanced, preventative optical solutions, is pleased to announce a major milestone in its regulatory pathway toward global market entry. Following a formal review meeting with the U.S. Food and Drug Administration ("FDA") on April 3, 2025, the FDA confirmed: Classification Agreement: EYEGUARD™ lenses are confirmed as Class I,...
2025-09-17 4:00 AM EDT